Quarterly report · Q2
3353.TEDINET S100S0UE
Period2023-03-01 → 2023-08-31
Filed2023-10-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥17.5bn | 2023-03-01 → 2023-08-31 | Cons. | Net sales |
| Revenue | ¥33.9bn | 2022-03-01 → 2023-02-28 | Cons. | Net sales (5-year summary) |
| Revenue | ¥17.0bn | 2022-03-01 → 2022-08-31 | Cons. | Net sales |
| Operating income | ¥603m | 2023-03-01 → 2023-08-31 | Cons. | Operating income |
| Operating income | ¥466m | 2022-03-01 → 2022-08-31 | Cons. | Operating income |
| Ordinary income | ¥697m | 2023-03-01 → 2023-08-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-03-01 → 2023-02-28 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥598m | 2022-03-01 → 2022-08-31 | Cons. | Ordinary income |
| Profit before tax | ¥776m | 2023-03-01 → 2023-08-31 | Cons. | Income before income taxes |
| Profit before tax | ¥624m | 2022-03-01 → 2022-08-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥444m | 2023-03-01 → 2023-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥760m | 2022-03-01 → 2023-02-28 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥374m | 2022-03-01 → 2022-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥469m | 2023-03-01 → 2023-08-31 | Cons. | Profit loss |
| Net income | ¥386m | 2022-03-01 → 2022-08-31 | Cons. | Profit loss |
| Total assets | ¥28.5bn | at 2023-08-31 | Cons. | Assets |
| Total assets | ¥27.5bn | at 2023-02-28 | Cons. | Assets |
| Total assets | ¥28.3bn | at 2022-08-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥15.4bn | at 2023-08-31 | Cons. | Liabilities |
| Total liabilities | ¥14.9bn | at 2023-02-28 | Cons. | Liabilities |
| Net assets / equity | ¥13.1bn | at 2023-08-31 | Cons. | Net assets |
| Net assets / equity | ¥12.6bn | at 2023-02-28 | Cons. | Net assets |
| Net assets / equity | ¥12.2bn | at 2022-08-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥6.7bn | at 2023-08-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.4bn | at 2023-02-28 | Cons. | Cash and deposits |
| Cash & equivalents | ¥6.5bn | at 2023-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.3bn | at 2023-02-28 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.8bn | at 2022-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.8bn | at 2022-02-28d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥848m | 2023-03-01 → 2023-08-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.3bn | 2022-03-01 → 2023-02-28 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥496m | 2022-03-01 → 2022-08-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥338m | 2023-03-01 → 2023-08-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥478m | 2022-03-01 → 2023-02-28 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥291m | 2022-03-01 → 2022-08-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥217m | 2023-03-01 → 2023-08-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.4bn | 2022-03-01 → 2023-02-28 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.2bn | 2022-03-01 → 2022-08-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥118.26 | 2023-03-01 → 2023-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥61.84 | 2023-06-01 → 2023-08-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥202.2 | 2022-03-01 → 2023-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥99.65 | 2022-03-01 → 2022-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥44.26 | 2022-06-01 → 2022-08-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 43.9% | at 2023-08-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.8% | at 2023-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.2% | at 2022-08-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-03-01 → 2023-08-31 | −¥472m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-03-01 → 2023-08-31 | −¥472m |
| Reconciling Itemsreconciling | segment profit | 2023-03-01 → 2023-08-31 | −¥387m |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥780m |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥300,000 |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥111m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥2.1bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥1.6bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥470m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥34m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥93m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥91m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥2m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥66m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-03-01 → 2023-08-31 | ¥17.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-03-01 → 2023-08-31 | ¥17.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥472m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-03-01 → 2023-08-31 | ¥990m |
| Reconciling Itemsreconciling | revenue | 2022-03-01 → 2022-08-31 | −¥497m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-03-01 → 2022-08-31 | −¥497m |
| Reconciling Itemsreconciling | segment profit | 2022-03-01 → 2022-08-31 | −¥385m |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2022-03-01 → 2022-08-31 | ¥11.6bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2022-03-01 → 2022-08-31 | ¥11.6bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2022-03-01 → 2022-08-31 | ¥736m |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue | 2022-03-01 → 2022-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue external | 2022-03-01 → 2022-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue intersegment | 2022-03-01 → 2022-08-31 | ¥300,000 |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | segment profit | 2022-03-01 → 2022-08-31 | ¥35m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue | 2022-03-01 → 2022-08-31 | ¥1.9bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2022-03-01 → 2022-08-31 | ¥1.4bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2022-03-01 → 2022-08-31 | ¥495m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2022-03-01 → 2022-08-31 | ¥20m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue | 2022-03-01 → 2022-08-31 | ¥95m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue external | 2022-03-01 → 2022-08-31 | ¥94m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue intersegment | 2022-03-01 → 2022-08-31 | ¥876,000 |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | segment profit | 2022-03-01 → 2022-08-31 | ¥61m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-03-01 → 2022-08-31 | ¥17.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-03-01 → 2022-08-31 | ¥17.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-03-01 → 2022-08-31 | ¥497m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-03-01 → 2022-08-31 | ¥851m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 499
| Item | Context | Value | Unit |
|---|---|---|---|
| Name major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)ハウス食品グループ本社株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)大阪府東大阪市御厨栄町１丁目５－７ | |
| Name major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)南野利久 | |
| Address major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)三重県津市 | |
| Name major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)株式会社サウス | |
| Address major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)三重県津市観音寺町４４６番地４２ | |
| Name major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)株式会社南野 | |
| Address major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)三重県津市観音寺町４４６番地４２ | |
| Name major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)東邦ホールディングス株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)東京都世田谷区代沢５丁目２－１ | |
| Name major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)メディカル一光グループ従業員持株会 | |
| Address major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)三重県津市西丸之内３６番２５号 | |
| Name major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Original text (Japanese)沢井製薬株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Original text (Japanese)大阪市淀川区宮原５丁目２－３０ | |
| Name major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)アルフレッサ株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)東京都千代田区内神田１丁目１２－１ | |
| Name major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)株式会社山陰合同銀行 | |
| Address major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)島根県松江市魚町１０番地 | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)株式会社メディカル一光グループ | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)三重県津市西丸之内36番25号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding gain on reversal of advance received (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |